TICKERNERD
Menu
BSXBSXHealthcare · Medical Devices

BSX Stock Forecast: Boston Scientific Corp. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$42
−1.45% on the day

The 31 Wall Street analysts covering Boston Scientific Corp. hold a median 12-month price target of $60 — +44.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 6 Oct 2026 — in the upper half.

Market cap
$61.4B
Ticker Nerd rank
55 / 100
Median analyst target
$60
Analysts covering
31
Revenue$5.4B+7.5% y/y
Operating income$1.2B
Net income$905.0M
Free cash flow−$451.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.7%
1M
−13.0%
YTD
−56.4%
1Y
−56.6%
From 52W high
−60.4%
From 52W low
0.0%
$42
$105
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BSX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Boston Scientific Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
55 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
94
Quality
89
Volatility
87
Growth
85
Issuance
62
Revisions
45
Accruals
37
Size
4
Momentum
4

Value (94): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (4): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BSX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BSX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100Jan 26Apr 26Jul 26Oct 26BSXHigh $94Median $60Low $44

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says31 analysts
25 Buy6 Hold0 Sell
Low $44Median $60High $94

The green dot is the last close — the median target sits +44.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 10 moved it down.

DateFirmActionRatingTarget
5 Oct 2026CitigroupMaintainsNeutral$50 → $48
24 Sept 2026Wells FargoMaintainsEqual-Weight$50 → $48
21 Sept 2026OppenheimerMaintainsOutperform$85 → $65
17 Sept 2026CitigroupDowngradeNeutral$57 → $50
9 Sept 2026BTIGMaintainsBuy—
9 Sept 2026BTIGMaintainsBuy$60 → $56
25 Aug 2026TD CowenReiteratesBuy$56
25 Aug 2026TD CowenReiteratesBuy—
31 July 2026Argus ResearchDowngradeHold—
31 July 2026Argus ResearchDowngradeHold—
30 July 2026Canaccord GenuityMaintainsBuy$70 → $66
30 July 2026Canaccord GenuityMaintainsBuy—
30 July 2026CitigroupMaintainsBuy—
30 July 2026CitigroupMaintainsBuy$70 → $61
30 July 2026Evercore ISI GroupMaintainsOutperform—
30 July 2026Evercore ISI GroupMaintainsOutperform$65 → $55
30 July 2026RBC CapitalMaintainsOutperform—
30 July 2026RBC CapitalMaintainsOutperform$85 → $70
30 July 2026TD CowenMaintainsBuy—
30 July 2026TD CowenMaintainsBuy$61 → $56

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BSX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BSX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Boston Scientific Corp. returned −56.6% against +17.7% for the S&P 500, dividends included.

BSX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26BSXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BSX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−2.8%
Analysts raising
0
Analysts cutting
25
Fundamentals

Boston Scientific Corp. (BSX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
17.1×

Cheaper than 42% of US stocks

Price / sales
2.9×

Cheaper than 41% of US stocks

Price / book
2.4×

Cheaper than 37% of US stocks

EV / EBITDA
12.9×

Cheaper than 28% of US stocks

Growth & margins
Revenue growth (YoY)
7.5%

Higher than 45% of US stocks

Earnings growth (YoY)
13.8%

Higher than 52% of US stocks

Gross margin
70.7%

Higher than 83% of US stocks

Operating margin
22.9%

Higher than 82% of US stocks

Net margin
17.5%

Higher than 80% of US stocks

Returns & dividend
Return on equity
15.3%

Higher than 75% of US stocks

Return on assets
6.2%

Higher than 82% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Boston Scientific Corp. (BSX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Boston Scientific Corp. has a market value of $61.4B and an enterprise value of $73.8B.

  • Revenue in the twelve months to 30 June 2026: $21.0B. The latest quarter grew 7.5% year on year.

  • Net income over the same four quarters: $3.7B, a 17.5% net margin.

  • Diluted earnings per share, trailing twelve months: $2.47.

  • Free cash flow in the twelve months to 30 June 2026: $1.8B.

  • Shares outstanding: 1.4B.

  • Trailing P/E: 17.1×; forward P/E: 12.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Boston Scientific Corp. employs 59,000 people — $356K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

BSX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BSXBoston Scientific Corp.$61.4B
55
EWEdwards Lifesciences Corp.$49.8B
90
SYKStryker Corp.$106.4B
72
MDTMedtronic PLC$111.7B
86
DXCMDexCom, Inc.$32.2B
99
GEHCGE Healthcare Technologies, Inc.$29.5B
61
ABTAbbott Laboratories$170.7B
56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Boston Scientific Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BSX news & analysis

Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer

PRNewsWire · 7 Oct 2026positive

Boston Scientific announced the appointment of Joseph M. Fitzgerald as executive vice president and chief operating officer. The company said the new operating structure is designed to increase efficiency and support continued growth.

Why it matters — The appointment and operating-structure change could affect how BSX organizes operations and pursues its stated efficiency and growth goals.

Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know

Zacks Investment Research · 2 Oct 2026negative

Boston Scientific (BSX) stock closed at $42.6 in the latest trading session, declining 1.46% from the previous day. The stock declined even as the broader market posted gains.

Why it matters — BSX watchers would note that the stock fell on a day when the overall market advanced, which could signal company-specific selling pressure.

Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

GlobeNewsWire · 1 Oct 2026neutral

Boston Scientific released the full $8 million held in escrow to Elutia on schedule and with no claims, in connection with the sale of the BioEnvelope business. Elutia stated the payment makes it fully funded through the first year of its expected NXT-41x launch and into 2029.

Why it matters — The release of the escrow payment concludes a financial obligation Boston Scientific owed under the BioEnvelope divestiture, settling the transaction on schedule without claims.

Boston Scientific's MedSurg Diversification Bolsters Growth Prospects

Zacks Investment Research · 30 Sept 2026positive

Zacks Investment Research reports that Boston Scientific's MedSurg segment is supporting the company's growth prospects, with gains in Endoscopy and Neuromodulation offsetting challenges in Urology and portfolio gaps.

Why it matters — A BSX watcher would care because the MedSurg division's strength highlights a source of momentum that helps counterbalance weaker areas within the company's portfolio.

Boston Scientific: Market Pessimism Has Pushed The Stock Into Undervalued Territory

Seeking Alpha · 29 Sept 2026neutral

Boston Scientific's stock fell 55% over 12 months due to weakness in electrophysiology and WATCHMAN, which account for only 26% of 2025 sales, while 74% of the business grew 7% in Q2 2026. Management cut 2026 guidance three times, lowering organic growth to 5-6% and EPS to $3.28-$3.32.

Why it matters — BSX watchers care because the report highlights that most of the business remains strong despite the market's heavy pessimism and repeated guidance cuts, suggesting the stock may be undervalued.

FAQ

Frequently asked questions about BSX stock

What is the BSX stock price forecast for 2026-2027?

The 31 Wall Street analysts covering Boston Scientific Corp. have a median 12-month price target of $60, with estimates ranging from $44 to $94. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BSX stock a buy right now?

Of the 31 analysts covering Boston Scientific Corp., 25 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Boston Scientific Corp. 55 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BSX?

As at 6 Oct 2026, Boston Scientific Corp. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (94 of 100).

Will BSX stock go up?

No one can know that. What the data says: the median 12-month target from 31 analysts implies +44.3% from the last close, and Ticker Nerd's factor model ranks Boston Scientific Corp. 55 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BSX stock forecast for 2030?

No analyst covering Boston Scientific Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BSX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $94 over the next 12 months.

How has BSX stock performed over the past year?

Boston Scientific Corp. returned -56.6% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Boston Scientific Corp. do?

Boston Scientific Corp. is a medical device company focused on developing, manufacturing, and marketing technologies used in interventional medical procedures worldwide.

What is the latest news on BSX?

The most recent item we track (PRNewsWire, 7 Oct 2026): "Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer". Boston Scientific announced the appointment of Joseph M. Fitzgerald as executive vice president and chief operating officer. The company said the new operating structure is designed to increase efficiency and support continued growth.

Company

About Boston Scientific Corp.

Boston Scientific Corp. is a medical device company focused on developing, manufacturing, and marketing technologies used in interventional medical procedures worldwide. The company’s portfolio serves a broad range of clinical areas, including cardiology, peripheral interventions, endoscopy, urology, and neuromodulation. Its MedSurg segment covers products for digestive health, urinary care, and pain management, while its Cardiovascular segment supports minimally invasive treatment options for heart and vascular conditions. Boston Scientific’s devices are designed to help healthcare professionals diagnose and treat patients through less invasive approaches across hospitals, clinics, and specialized medical centers. Headquartered in Marlborough, Massachusetts, Boston Scientific plays a significant role in the global health care equipment market through its broad mix of procedure-based products and physician-focused solutions.

CEO Mr. Michael F. Mahoney · 59,000 employees · United States · https://www.bostonscientific.com